Human papilloma virus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus. Available vaccines protect against either two, four or nine types of HPV. All vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer. It is estimated that the vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer and possibly some mouth cancer. They additionally prevent some genital warts, with the vaccines against HPV types 4 and 9 providing greater protection.
Sample Chapter(s)
Preface (179 KB)
Components of the Book:
- Chapter1
Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)
- Chapter2
Dr. Jian Zhou: The great inventor of cervical cancer vaccine
- Chapter3
Social and cultural construction processes involved in HPV vaccine hesitancy among Chinese women: a qualitative study
- Chapter4
Knowledge of cervical cancer and HPV vaccine in Bangladeshi women: a population based, cross-sectional study
- Chapter5
Determination of knowledge levels, attitude and behaviors of female university students concerning cervical cancer, human papiloma virus and its vaccine
- Chapter6
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti- PD-1 immunotherapy in preclinical model of HPV+ oral cancer
- Chapter7
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
- Chapter8
TCR-like antibodies in cancer immunotherapy
- Chapter9
Human papillomavirus vaccine uptake in adolescence and adherence to cervical cancer screening in Switzerland: a national cross-sectional survey
- Chapter10
Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04 adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
- Chapter11
Inclusion of the benefits of enhanced crossprotection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
- Chapter12
Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign
- Chapter13
Recurrent sick leave and resignation rates among female cancer survivors after return to work: the Japan sickness absence and return to work (J-SAR) study
- Chapter14
Human papilloma virus (HPV) genotypes concordance between Iranian couples referrals
- Chapter15
Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to human papilloma virus vaccination
Readership:
Students, academics, teachers and other people attending or interested in medicine or health care.
Elisa J Young, Department of Microbiology and Infectious Diseases Royal Women’s Hospital, Melbourne , Australia
Shalini L Kulasingam, Dept. of Obstetrics and Gynecology, Duke University, Durham, USA
Ruanne V Barnabas, Cancer Epidemiology Unit, University of Oxford, Oxford, UK
Ann Levin, Independent consultant, Bethesda, USA
Nathalie Broutet, Reproductive Health and Research (RHR) Department, WHO, Geneva 27, Switzerland
Afsana Bhuiyan, London North West Healthcare NHS Trust,London,UK
and more...